Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 6, 2012, Pages 695-701

  Zhou, Liping ^a   Chen, Huan ^a   Wen, Quan ^a   Zhang, Yan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

immunohistochemistry; indoleamine 2,3 dioxygenase; inflammatory bowel disease

Indexed keywords

CHLORDANE; GLYCOPROTEIN P 15095; INDOLEAMINE 2,3 DIOXYGENASE; INFLIXIMAB; SALICYLIC ACID DERIVATIVE; STEROID; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ANTIBODY;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; CROHN DISEASE; CYTOPLASM; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; ENZYME INDUCTION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; INTESTINE EPITHELIUM; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD11C; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; COLITIS, ULCERATIVE; CROHN DISEASE; EPITHELIAL CELLS; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOENZYME TECHNIQUES; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MIDDLE AGED; SALICYLATES; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862788118     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328351c1c2     Document Type: Article

References (27)

1. Gonzalez MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviates experimental colitis by inhibiting inflammatory and autoimmune response. Gastroenterology 2009;136:978-989.
2. Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, et al. Indoleamine 2, 3-dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002;51:356-365.
3. Xu H, Oriss TB, Fei M, Henry AC, Melgert BN, Chen L, et al. Inoleamine 2, 3-dioxygenase in lung dendritic cells promotes the responses and allergic inflammation. Proc Natl Acad Sci USA 2008;105:6690-6695.
4. Lan Z, Ge W, Arp J, Jiang J, Liu WH, Gordon D, et al. Induction of kidney allograft tolerance by soluble CD83 associated with prevalence of tolerogenic dendritic cells and indoleamine 2, 3-dioxygenase. Transplantation 2010;90:1286-1293.
5. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992;257:789-792.
6. Gurtner GJ, Newberry RD, Schloemann SR, McDonald KG, Stenson WF. Inhibition of indoleamine 2, 3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 2003;125:1762-1173.
7. Jasperson LK, Bucher C, Panoskaltsis-Mortari A, Mellor AL, Munn DH, Blazar BR. Inducing the tryptophan catabolic pathway, indoleamine 2, 3-dioxygenase (IDO), for suppression of graft-versus-host-disease (GVHD) lethality. Blood 2009;114:5062-5070.
8. Oshitani N, Campbell A, Kitano A, Kobayashi K, Jewell DP. In situ comparison of phenotypical and functional activity of infiltrating cells in ulcerative colitis mucosa. J Pathol 1996;178:95-99.
9. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1997;114:262-267.
10. Maneechotesuwan K, Ekjiratrakul W, Kasetsinsomabat K, Wongkajornsilp A, Barnes PJ. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol 2010;126:754-762.e1.
11. Inglis JJ, Criado G, Andrews M, Feldmann M, Williams RO, Selley ML. The anti-allergic drug, N-(3', 4'-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis. Rheumatology 2007;46:1428-1432.
12. Yan Y, Zhang GX, Gran B, Fallarino F, Yu S, Li H, et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell response in experimental autoimmune encephalomyelitis. J Immunol 2010;185:5953-5961.
13. Anna MW, Dominik W, Holger R, Alexander RM, Arthur K, Peter O, et al. Overexpression of indoleamine 2, 3-dioxygenase in human inflammatory bowel disease. Clin Immunol 2004;113:47-55.
14. Matthew AC, Ellen EB, Keely GM, Richard M, George CP, Rodney DN, et al. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental Colitis. J Immunol 2010;184:3907-3916.
15. Ferdinande L, Demetter P, Perez-Novo C, Waeytens A, Taildeman J, Rottiers I, et al. Inflamed intestinal mucosa features a specific epithelial expression pattern of indoleamine 2, 3-dioxygenase. Int J Immunopathol Pharmacol 2008;21:289-295.
16. Matteoli G, Mazzini E, Iliev ID, Mileti E, Fallarino F, Puccetti P, et al. Gut CD103 + dendritic cells express indoleamine 2, 3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut 2010;59:595-604.
17. Paveglio SA, Allard J, Foster H, Ather JL, Bevelanger M, Campbell JM, et al. Airway epithelial indoleamine 2, 3-dioxygenase inhibits CD4 + T cells during Aspergillus fumigates antigen exposure. Am J Respir Cell Mol Biol 2011;44:11-23.
18. Onodera T, Jang MH, Guo Z, Yamasaki M, Hirata T, Bai ZB, et al. Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of CTLA-4/B7 and CCL22/CCR4 interaction. J Immunol 2009;183:5608-5614.
19. Von Bubnoff D, Scheler M, Wilms H, Wenzel J, von Bubnoff N, Häcker G, et al. Indoleamine 2, 3-dioxygenase-expression myeloid dendritic cells and macrophages in infectious and noninfectious cutaneous granulomas. J Am Acad Dermatol 2011;65:819-832.
20. Mahannonda R, Sa-Ard-lam N, Montreekachon P, Pimkhaokham A, Yongvanichit K, Fukuda MM, et al. IL-8 and IDO expression by human gingival fibroblasts via TLRs. J Immunol 2007;178:1151-1157.
21. Teleshova N, Kenney J, Jones J, Marshall J, Van Nest G, Dufour J, et al. CpG-C immunostimulatory oligodeoxyribonucletide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells. J Immunol 2004;173:1647-1657.
22. Hayashi T, Raz Eyal. TLR9-based immunotherapy for allergic disease. Am J Med 2006;119:897. e1-897.e6.
23. O'Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2, 3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009;29:4200-4209.
24. Türck J, Oberdorfer C, Vogel T, MacKenzie CR, Däubener W. Enhancement of antimicrobial by glucocorticoids. Med Microbiol Immunol 2005;94(1-2):47-53.
25. Snijdewint FG, Kapsenberg ML, Wauben-Penris PJ, Bos JD. Corticosteroids class-dependently inhibit in vitro Th1-and Th2-type cytokine production. Immunopharmacology 1995;29:93-101.
26. Crotty B, Rosenbery WM, Aronson JK, Jewell DP. Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease. Gut 2002;33:1353-1357.
27. English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007;110:91-100.